Skip to main content

Breadcrumb

  1. Home

Thiamine as a Renal Protective Agent in Septic Shock

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Thiamine as a Renal Protective Agent in Septic Shock

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 203
  • Page 204
  • Page 205
  • Page 206
  • Page 207
  • Page 208
  • Page 209
  • Page 210
  • Page 211
  • …
  • Next page Next
  • Last page Last
Subscribe to